Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C.S. Rufino is active.

Publication


Featured researches published by C.S. Rufino.


Value in Health | 2015

Budget Impact Analysis Of Tofacitinib For Rheumatoid Arthritis From The Perspective Of The Brazilian Private Healthcare System

C.N. Ferreira; C.S. Rufino; C.F.S.D. Santana; M Dulcine

Tofacitinib is an active immunosuppressant: oral administration (unnecessary cold chain) acts as a potent and selective inhibitor of Janus kinase family (JAK), more specifically JAK3 and JAK1, with an important role in cytokine signal transduction that regulates survival, proliferation, differentiation and apoptosis of lymphocytes4. adequate response in monotherapy. may provide multiple benefits for patients, doctors . short half-life. innovative mechanism of action is considered beneficial to patients non-responsive to current therapy DMARD.4


Value in Health | 2014

Economic Burden of Hospitalized Pneumonia from a Private Health Care System Perspective in Brazil

D.F. Manfrin; C.N. Ferreira; C.F.S.D. Santana; E.D.M.P. Paloni; F.D.S. Campi; Y. Gea; C.S. Rufino

REFERENCES Costs related to pneumonia hospitalization are high and represents a large impact to the total budget expenditures in the Brazilian private healthcare system. Given that the cost for a pneumonia hospitalization is much higher than an average hospitalization, there is a need to better implement pneumonia prevention strategies such as flu and pneumococcal vaccinations and smoking cessation. This study aimed to evaluate the economic burden of hospitalized pneumonia and its associated costs in the Brazilian Private Health System.


Value in Health | 2014

Costs of Pneumonia in Patients With Cancer Diagnosis from the Private Health System Perspective in Brazil.

D.F. Manfrin; C.N. Ferreira; C.F.S.D. Santana; E.D.M.P. Paloni; F.D.S. Campi; Y. Gea; C.S. Rufino

REFERENCES Although the number of pneumonia hospitalization per patient was slightly higher in WCa compared with WoCA patients, the cost per patient and cost per hospitalization was at least 3 times higher in the WCa compared with WoCA patients. The data analyzed show that the oncological therapies represent only about 1.2% of the total cost of expenses of care in oncology, which demonstrates the need for a series of specialized care that is necessary with this type of patient, not just spending with cancer. Given that cancer patients are susceptible to many infections, including pneumonia, strategies to reduce risk of infection should be prioritized. For pneumonia prevention, flu and pneumococcal vaccinations are indicated. Cancer patients are susceptible to infections, including pneumonia, due to immunosuppressive therapies associated with cancer treatment. This study aimed to evaluate the budget impact of pneumonia in patients with previous diagnosed cancer in the Brazilian Private Health System.


Value in Health | 2015

Lung Cancer Economic Burden From a Private Healthcare System Perspective In Brazil

C.N. Ferreira; C.F.S.D. Santana; E.D.M.P. Paloni; F.D.S. Campi; C.S. Rufino


Value in Health | 2015

Acromegaly Patients with Inadequate Response to Maximum Dose Octreotide-Lar Who Progress to Treatment with Pegvisomant: Economic Evaluation and Incremental Budget Impact Analysis from the Public Perspective to São Paulo State

C.N. Ferreira; C.S. Rufino; C.F.S.D. Santana


Value in Health | 2015

Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) in Public and Private System Versus Ppsv23 and No Vaccination in Older Adults

C.N. Ferreira; C.F.S.D. Santana; C.S. Rufino


Value in Health | 2014

Budget Impact Analysis of 13-Valent Pneumococcal Vaccine in Adult Population with Comorbidities or Immunocompromised from the Public Payer Perspective In Brazil.

C.N. Ferreira; D.F. Manfrin; C.S. Rufino; Y. Gea; L.C. Haas; R.A. Fernandes


Value in Health | 2014

Financial Analysis Of A Vaccination Campaign Using 13 Valent Pneumococcal Conjugated Vaccine (PCV13) With Employers

C.N. Ferreira; D.F. Manfrin; C.S. Rufino


Value in Health | 2015

Inadequate Treatment of Post-Surgical Pain May Result in Extended Hospitalization Period.

C.N. Ferreira; C.F.S.D. Santana; C.S. Rufino; Paloni Ed; Ec Paiva; L Fahham; Ap Ribeiro; Dd Mazza


Value in Health | 2015

Assessment of Tofacitinib For Rheumatoid Arthritis From The Perspective of The Brazilian Healthcare System

C.N. Ferreira; C.S. Rufino; C.F.S.D. Santana; M Dulcine

Collaboration


Dive into the C.S. Rufino's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dd Mazza

Federal University of São Paulo

View shared research outputs
Researchain Logo
Decentralizing Knowledge